

1 **Model-based cellular kinetic analysis of SARS-CoV-2 infection:**
2 **different immune response modes and treatment strategies**

3 Zhengqing Zhou^{1*}, Ziheng Zhao^{2*}, Shuyu Shi^{3*}, Jianghua Wu^{4*}, Dianjie Li¹, Jianwei Li¹, Jingpeng
4 Zhang¹, Ke Gui², Yu Zhang², Heng Mei^{4#}, Yu Hu^{4#}, Qi Ouyang^{1#}, and Fangting Li^{1#}

5
6 ¹ School of Physics, Center for Quantitative Biology, Peking University, Beijing 100871, China

7 ² Department of Immunology, School of Basic Medical Sciences, NHC Key Laboratory of Medical
8 Immunology, Peking University, Beijing 100191, China.

9 ³ Peking University Third Hospital, Peking University, Beijing 100191, China.

10 ⁴ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science
11 and Technology, Wuhan, 430022, China

12

13 * These authors contribute equally to this work

14 # To whom correspondence should be addressed. dr_huyu@126.com, hmei@hust.edu.cn,

15 qi@pku.edu.cn, lft@pku.edu.cn

16

17

18

19 **Abstract**

20 Increasing number in global COVID-19 cases demands for mathematical model to
21 analyze the interaction between the virus dynamics and the response of innate and
22 adaptive immunity. Here, based on the assumption of a weak and delayed response of
23 the innate and adaptive immunity in SARS-CoV-2 infection, we constructed a
24 mathematical model to describe the dynamic processes of immune system. Integrating
25 theoretical results with clinical COVID-19 patients' data, we classified the COVID-19
26 development processes into three typical modes of immune responses, correlated with
27 the clinical classification of mild & moderate, severe and critical patients. We found that
28 the immune efficacy (the ability of host to clear virus and kill infected cells) and the
29 lymphocyte supply (the abundance and pool of naïve T and B cell) play important roles
30 in the dynamic process and determine the clinical outcome, especially for the severe and
31 critical patients. Furthermore, we put forward possible treatment strategies for the three

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 typical modes of immune response. We hope our results can help to understand the
33 dynamical mechanism of the immune response against SARS-CoV-2 infection, and to
34 be useful for the treatment strategies and vaccine design.

35 **Introduction**

36 Coronavirus disease 2019 (COVID-19) caused by the coronavirus SARS-CoV-2 has
37 spread globally, having a huge impact on global politics, economy and society.
38 Compared to other viral infectious diseases, such as influenza, severe acute respiratory
39 syndrome (SARS), Middle East respiratory syndrome (MERS), and acquired immune
40 deficiency syndrome (AIDS), COVID-19 exhibits multiscale different characteristics.
41 Epidemiologically, COVID-19 has a relatively longer incubation period (~5.8 days) with
42 a number of asymptomatic patients, which intensifies the difficulty of management and
43 prevention (1). For the within-host viral infection, about 80% COVID-19 patients exhibit
44 mild symptoms and recover within 3~4 weeks after regular treatments (2). The severe
45 and critical COVID-19 patients (~20%) are related to lymphopenia, high neutrophil
46 counts and cytokine release syndrome (CRS) or cytokine storm, characterized by
47 elevated inflammatory cytokines levels like IL-6. CRS and succeeding comorbidities
48 usually cause bad clinical outcome and even death, although the overall intensity of the
49 cytokine storm in COVID-19 patients is milder than SARS patients (3).

50 More studies and evidences show that the SARS-CoV-2 virus, compared to SARS-
51 CoV and MERS-CoV, in the early infection period tends to induce less effective anti-
52 viral innate immune responses with a delayed or lower type-I interferon (IFN) response
53 and lower HLA-II expression level (4, 5). Furthermore, marked lymphopenia and
54 impaired humoral immunity with the loss of germinal centers (6) suggest that the weak
55 adaptive immune response could contribute to damped clearance of virus and thus
56 chronic infection.

57 Though the knowledge and clinical data of COVID-19 is increasing, a systemic view
58 of immunologic response in SARS-CoV-2 infection remains necessary. Due to the
59 variance in immune status and response dynamic processes among patients, it is hard to
60 make up an effective therapeutic schedule, for example, the effects of remdesivir, IFN- γ
61 and antibodies remain controversial (7-13).

62 Here, we investigated the immune response against SARS-CoV-2 infection by
63 analyzing the longitudinal hemogram data of 194 patients from Wuhan Union Hospital

64 and also by mathematical modeling the within-host immune dynamics. We constructed
65 within-host virus-immune interaction network, together with a mathematical model
66 depicting the dynamic processes and the response of the innate immunity and adaptive
67 immunity against SARS-CoV-2 infection. We simulated and classified the different
68 modes of patient's immune responses, which correspond to the longitudinal data of
69 COVID-19 patients, and we propose the possible treatment strategies to improve the
70 immune status of COVID-19 patients.

71 **Immune network and model, immune efficacy and T cell supply**


72 The human immune system is a complex defense system involving dozens of
73 different cell types and hundreds of interacting molecular pathways, protecting human
74 body from dangerous pathogens. A mathematical model, which describes the complex
75 interactions in immune system and the demographic differences in patient's health
76 status, should help us to understand the underlying immune response, to classify the
77 patients based on their immune response processes, and provide possible definitive
78 treatment strategies.

79 We analyzed 194 COVID-19 patients' longitudinal data from Union Hospital of
80 Tongji Medical College in Huazhong University of Science and Technology (Wuhan,
81 P. R. China), including the hemogram, the serum cytokine profile and treatments at
82 different time points, as well as their clinical classification and outcome. We found that
83 among mild, severe and critical COVID-19 patients, the time sequences of counts of
84 white blood cell, neutrophil and lymphocyte, together with IL-6 levels in peripheral
85 blood behave significant different, indicating the severity of patients (Fig. 2B). In
86 critical patients, the elevated neutrophil counts and myeloid-derived suppressor cell
87 (MDSC) fraction are significantly greater than the mild and severe patients, which
88 could be accredited to the chronic viral and bacterial co-infection (Fig. S5B).

89 Based on the recent evidences and clinical data about COVID-19, we put forward a
90 possible immune mechanism during SARS-CoV-2 infection: a slow innate immune
91 response in the early infection stage leading to extensive tissue damage and
92 inflammation, and a weak adaptive immune response in later stage resulting in the
93 chronic infection and bad clinical outcome.

94 We simplified both innate and adaptive immune response processes within-host
95 caused by the SARS-CoV-2 infection, and constructed a virus-immune interaction
96 network with the viral infection module, innate immunity, cellular immunity, humoral
97 immunity, and immunosuppression modules (Fig. 1). During the SARS-CoV-2 infection,
98 infected lung epithelial cells recruit innate immune cells through chemokine secretion,
99 including neutrophils (Neut), macrophages ($M\Phi$), dendritic cells (DC), and natural killer
100 cells (NK). These cells serve as the initial immune defense in the virus-immune
101 interaction network against the virus, and secrete the inflammatory cytokines like IL-6
102 and TNF- α . The DC and $M\Phi$ engulf and process SARS-CoV-2 specific antigens they
103 encounter, and then they work as antigen-presenting cells (APC) to activate naïve T and
104 B cells. The activated CD4⁺ and CD8⁺ T cells proliferate and differentiate into effective
105 helper T cells (Th) and cytotoxic T cells (CTL), then travel to the airway and lung
106 fighting against the pathogens. Meanwhile, the germinal centers in lymph nodes form
107 around the pathogen-loaded dendritic cells, where naïve B cells go through affinity
108 maturation with clonal selection and differentiate into plasma cells that produce
109 immunoglobulin (Ig) to clear the virus. During this process, regulatory T cells (Treg) are
110 also activated to prevent the over activation of immune system and turn off the immune
111 response when the virus is cleared.

112 For the sake of simplicity and clarity of the model, we made the following main
113 simplifications and assumptions. (1) We focus on the host immune response in lung
114 and nearby draining lymph nodes (lung area). (2) IL-6 is selected as the key indicator
115 of inflammation. (3) To compare with clinical data, we add the antiviral drug term
116 (parameter α in Eq.2) in our model. (4) We discuss the primary virus infection and
117 immune response, and ignore the process and function of SARS-CoV-2-specific
118 memory T and B cells. (5) The cytokine level in lung is estimated to be 10 times of the
119 peripheral blood cytokines, providing a reference for comparison between modeling
120 results and clinical data. More details about the interactions among virus, immune cells
121 and cytokines can be found in Table 1 of Supplemental Material (SM), and our other
122 assumptions are listed in section 1.2 of SM.



123

124 Fig. 1. The immune system response network against SARS-CoV-2 infection. (A) The network can be
 125 divided into five modules: viral infection, innate immunity, cellular immunity, humoral immunity and
 126 immunosuppression modules, each part including complex and nonlinear interactions among immune
 127 cells and cytokines. (B) The overall interactions among the five modules.

128 Then we built a 24-variable ODE model to depict the dynamical process of immune
 129 response against SARS-CoV-2 infection. Clinical data and results, together with the
 130 evidence on the lower IFN-I response (4, 5), provide a reference for the construction
 131 and parameterization of the model. In lung area, we define $[nCoV]$ as the concentration
 132 of free viral load, $[H]$ and $[If]$ denote respectively the concentrations of healthy
 133 pulmonary epithelial cell and productively infected cell. The concentrations of
 134 neutrophils, APC (DC and $M\Phi$), natural killer cells and cytotoxic T lymphocytes
 135 (CTL) are denoted as $[Neut]$, $[APC]$, $[NK]$ and $[CTL]$ respectively. $[Ig]$ is the
 136 concentration of antibodies. The viral load and lymphocytes are in the unit of $10^6/mL$,

137 the unit of cytokines is pg/mL, and the unit of antibodies is $\mu\text{g/mL}$.

138 In the viral infection module, we have the following equations to depict how the
139 SARS-CoV-2 virus infects the lung epithelial cells.

$$140 \quad \frac{d[nCoV]}{dt} = \gamma N_1 d_{If} [If] - (k_1^{clear} [Neut] + k_2^{clear} \cdot A \cdot [Ig]) [nCoV] \quad (1)$$

$$141 \quad \frac{d[If]}{dt} = \alpha k_{infect} [nCoV] [H] - \{k_1^{kill} [APC] + k_2^{kill} [NK] + k_3^{kill} [CTL]\} [If] - d_{If} [If] \quad (2)$$

$$142 \quad \frac{d[H]}{dt} = r_H - \alpha k_{infect} [nCoV] [H] - d_H [H] \quad (3)$$

143 The viral dynamics is described in Eq.1. The virion particles are produced from
144 infected cells at the rate of $\gamma N_1 d_{If} [If]$, where γ stands for a conversion factor between
145 particle count and extracellular particle number density, N_1 is the burst size of SARS-
146 CoV-2 virus, d_{If} is the death rate of infected cells that release new virions. The viruses
147 are cleared by neutrophils $[Neut]$ and antibodies $[Ig]$ at the rate of
148 $(k_1^{clear} [Neut] + k_2^{clear} \cdot A \cdot [Ig]) [nCoV]$. In Eq.2, the epithelial cells are infected by free
149 virions at rate $\alpha k_{infect} [nCoV] [H]$, where α stands for the effect of antiviral drugs,
150 k_{infect} is the infection rate of virus. The infected cells are killed by APC (DC and M Φ),
151 natural killer cells and CTL at the rate $\{k_1^{kill} [APC] + k_2^{kill} [NK] + k_3^{kill} [CTL]\} [If]$. The
152 infected cells die at rate $d_{If} [If]$ and release new free virion particles. In Eq.3, the
153 healthy lung epithelial cells regenerate at the rate r_H and undergo normal apoptosis at
154 rate $d_H [H]$.

155 We define $e^{kill}(t) \equiv k_1^{kill} [APC] + k_2^{kill} [NK] + k_3^{kill} [CTL] + d_{If}$ and

156 $e^{clear}(t) \equiv k_1^{clear} [Neut] + k_2^{clear} \cdot A \cdot [Ig]$. Under adiabatic approximation of change of the

157 infected cells, we have $\frac{d[nCoV]}{dt} = e^{clear}(R_0 - 1)[nCoV]$, where the reproductive ratio

158 is defined as $R_0 \equiv \frac{\alpha \gamma N_1 d_{If} k_{infect} [H]}{e^{clear} \cdot e^{kill}}$. To represent the ability of immune system to

159 clear the virus and kill the infected cells, we define the host immune efficacy at time

160 point t as $e(t) \equiv e^{clear}(t) e^{kill}(t)$. Thus, at time point t , if $R_0(t) < 1$ and

161 $e(t) > \alpha \gamma N_1 d_{If} k_{infect} [H]$, the population of virus will decrease; otherwise the population

162 of virus will increase.

163 When the naïve CD8+T cells meet and interact with antigen-loaded APCs in the
164 lymph nodes, they are activated, proliferate and differentiate to CTL, then move to the
165 lung area to fight against the virus. We use a logistic term to describe the homeostasis of
166 naïve CD8+ T cell supply with capacity K_{CD8} and growth rate r_{CD8} , k_{CTL} represents the
167 activation rate to CTL from the naïve CD8+ T cell by APC interaction. Thus, we wrote
168 the dynamics of naïve CD8+T cell as:

$$169 \quad \frac{d[CD8^+T_0]}{dt} = r_{CD8}[CD8^+T_0] \left(1 - \frac{[CD8^+T_0]}{K_{CD8}} \right) - k_{CTL} \frac{[APC]^5}{K_A^5 + [APC]^5} [CD8^+T_0] \quad (4)$$

170 Steady state solution gives out $[CD8^+T_0] = \left(1 - \frac{k_{CTL}}{r_{CD8}} \cdot \frac{[APC]^5}{K_A^5 + [APC]^5} \right) K_{CD8}$. We define

171 the host supply ability of naïve CD8+T cell as $s_{CD8} \equiv \frac{r_{CD8}}{k_{CTL}} \frac{K_A^5 + [APC]^5}{[APC]^5}$, which

172 indicates the ability of CD8+ T cell supply to produce more CTL. If $s_{CD8} > 1$, there
173 will have sufficient naïve CD8+T cell. Once chronic infection takes place, the patients
174 with $s_{CD8} < 1$ might experience CD8+ T cell exhaustion. When $[APC] > K_A$,

175 $s_{CD8} \rightarrow \frac{r_{CD8}}{k_{CTL}}$. Thus, the host supply ability s_{CD8} determine whether the CD8+ T cell

176 pool can supply more CTL cells in the ‘killing’ infected cell process, which works as
177 $k_3^{kill}[CTL]$ term in the $e^{kill}(t)$ and $e(t)$. Similar supply analysis and results can be
178 applied to CD4+ T cells.

179 More details concerning immune cell and cytokine dynamics can be found in the
180 section 2 of SM.

181 Furthermore, we also utilized the model to simulate other viral infectious diseases,
182 including influenza and severe acute respiratory syndrome (SARS). The differences in
183 virus infection rate, burst size and activation strength of the immune system lead to
184 significant differences in epidemical features among influenza, SARS and SARS-CoV-
185 2, especially the incidence rate, incubation period and critical rate. Detailed parameter
186 settings and results are shown in the section 3 of SM.

187 **Modeling typical modes of immune response against SARS-CoV-2**


188 Demographically, the immune system's capability and response vary individually,
189 susceptible to age, fitness and gender differences (14, 15). In Fig. 2A, we adopted
190 Latin hypercube sampling method (16) to search across the parameter space and
191 identified three typical modes of the immune responses against SARS-CoV-2 infection,
192 where they differ in the extent of tissue damage, final state viral load and immune
193 response, in particular the levels of host immune efficacy e and supply ability s_{CD8} .
194 We also defined asymptomatic patients by underactive immune and inflammatory
195 response. Full trajectory of the three immune modes and asymptomatic patients can be
196 found in Fig. S2A and their definitions in Table S2 of SM. Parameter sample range and
197 initial value choice can be found in section 7 of SM. Sampled curves are aligned at
198 $[nCoV]=10^6/mL$.

199 During the early stage of infection, the post admission days (PAD) 0~7, a faster and
200 stronger innate immunity is evoked in the mode 1 patients, protecting lung tissue from
201 viral damage. For the mode 2 and 3 patients, delayed and weaker innate immunity
202 brings about more extensive damages with higher viral load, manifested in Fig. S2C
203 and D of SM. During the middle stage (PAD 7~14), the adaptive immunity of mode 1
204 and 2 patients is built up successfully, providing the patients with strong immune
205 efficacy, averaged at $e_{max} > 12$, which is enough to clear the virus and kill the infected
206 cells. For the mode 2 patients, the accumulated tissue damage at early stage over-
207 activates the innate immunity, especially neutrophils and monocytes and thus causes
208 temporary cytokine storm. The mode 3 patients' immune response stays low at about
209 $e = 3.5$, possibly attributed to limited antibody production and inadequate CD8+ T cell
210 supply. During the late stage (PAD 14+), the mode 1 and 2 patients recover from the
211 infection, however the mode 3 patients experience chronic infection and 23% end up
212 with naïve CD8+T cell pool insufficiency (denoted as insufficient s_{CD8}). Time course of
213 $1/s_{CD8}$ and e of the three modes are shown in Fig. 2C and Fig. 2D.

214 In comparison to mode 2, mode 3 is more likely to appear in older patients with
215 underlying diseases, including but not limited to hypertension and diabetes mellitus,
216 for their fragile immune systems. This view is also supported by recent study on the
217 association between adaptive immunity and age (18). In addition to these, in mode 3,

218 long-termed damage of lung epithelial cells and inadequate immune efficacy could
 219 possibly induce secondary bacterial or fungal infection, discussed in section 7 of SM,
 220 thus lead to overactive inflammatory response and cytokine storm. Therefore, patients
 221 with mode 3 response are more likely to be critical and should be paid with extra
 222 attention.

223 Figure 2.



224

225 Fig. 2. Sampling result of host immune response against SARS-CoV-2 infection. (A)
 226 Schematic illustration of three typical modes of immune response, the sampled curves are aligned
 227 at $[nCoV]=10^6/mL$. Innate immunity is defined by the summation of APC and NK density,
 228 cellular immunity is defined by CTL density and humoral immunity is defined by antibody level.
 229 (B) Time course of immune efficacy e of the three immune modes. During early stage, mode 1
 230 has higher e compared to mode 2 and 3, leading to less extensive tissue damage and thus milder
 231 level of cytokine storm. At around day 14, e value of mode 1 and 2 rises to the peak,
 232 corresponding to the fully activation of immune system. Meanwhile, mode 3 patients do not show
 233 the peak, suggesting underactive adaptive immunity leads to chronic infection. (C) Time course of
 234 inverted CD8+ T cell supply $1/s_{CD8}$ of mode 1, 2 and 3. Both mode 1 and 2 pass $s_{CD8} < 1$
 235 temporarily, corresponding to the maximum activation from innate immunity to adaptive
 236 immunity, while mode 3 patients show a durative $s_{CD8} < 1$, leading to insufficient CD8+ T cell
 237 supply. (D) Mode 3 patients are further divided in to naïve CD8+T cell insufficient ones
 238 (insufficient s_{CD8}) and sufficient ones (sufficient s_{CD8}).

239 **Classification of patients and relevant treatment strategies**

240 To understand the dynamical features and processes of COVID-19 patients'
241 immune response, we investigated the longitudinal data of hemogram and cytokine
242 profile of 64 patients (out of 194 patients) with multiple cytokine data points (≥ 4)
243 from Wuhan Union Hospital in China. All patients were divided into mild & moderate,
244 severe and critical groups based on their clinical symptoms, according to the 7th
245 Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance (19).

246 Here we mainly focus on the immune response features of the COVID-19 patients,
247 which imposes huge impact on patient's clinical status. Similar to the immune efficacy
248 e , we define the clinical efficacy of innate and adaptive cellular immunity of patients
249 as $e^*(t) = Neut\%(t) \times [Monocyte\%(t) + Lymphocyte\%(t)]$, where $Neut\%(t)$,
250 $Monocyte\%(t)$, $Lymphocyte\%(t)$ are respectively the proportion of neutrophils,
251 monocytes and lymphocytes in peripheral blood at time point t .


252 In Fig. 3A, we classified the patients by their IL-6 level and averaged e^* value (\bar{e}^*)
253 into three classes. The class 1 profile (31 patients) has $\bar{e}^* > 0.15$ and
254 $IL-6_{\max} < 200$ pg/mL, includes 15 mild patients and 16 severe patients. The class 2
255 profile (20 patients) has $\bar{e}^* > 0.15$ and $IL-6_{\max} > 200$ pg/mL, includes 9 mild, 10
256 severe and 1 critical patient. The class 3 profile (8 patients) has $\bar{e}^* < 0.15$ and
257 $IL-6_{\max} > 200$ pg/mL, includes 1 severe and 7 critical patients. 5 patients belong to none
258 of the above groups and are taken as exceptions.

259 In Fig. 3B, we aligned and averaged the time course of the three classes patients'
260 peripheral blood cell and cytokine profile. We particularly fixed the class 2 and 3
261 patients' IL-6 peak at the 30th day and smoothed the curve using a triple-window
262 averaging method (see this method in section 5.1 of SM). Time series data of the three
263 classes patients differ significantly in the neutrophil, lymphocyte, IL-6, IL-10 level and
264 immune efficacy. The class 1 patients exhibit low neutrophil counts, low IL-6 level
265 (milder inflammatory response), high lymphocyte counts and high e^* level, indicating
266 mild symptom and effective immune response. The class 1 patients are less likely to
267 develop into critical cases and would recover smoothly. The class 2 patients show

268 temporarily stronger inflammatory response (higher IL-6 level) than the class 1, whose
 269 IL-6 peak usually has a 3-day full width at half maximum (FWHM). The class 3
 270 patients show a longer period of cytokine storm status with IL-6 peak and a 13-day
 271 FWHM. In addition, the class 3 patients with lymphopenia and low e^* value suggest
 272 the incompetent immune response and possible exhaustion of T cells; the significantly
 273 elevated level of neutrophils and IL-10 peak with a 7-day FWHM might indicate the
 274 occurrence of secondary bacterial infection and the emergence of MDSC, both could
 275 attribute to chronic infection and poor clinical outcome.

276 Thus, we correspond the class 1, 2 and 3 COVID-19 patients to the *in silico* mode
 277 1, 2 and 3 immune response against SARS-CoV-2 infection respectively. We hope our
 278 immunity-based classification method can serve as an indicator of patient's immune
 279 response and clinical conditions.

280 **Figure 3.**



281
 282 Fig. 3. The 64 clinical patients are classified by their IL-6 level and the immune efficacy in peripheral
 283 blood. (A) We identify 31 patients as the class 1 profile (15 mild & moderate patients, 16 severe patients),
 284 20 patients as the class 2 profile (9 mild & moderate patients, 10 severe patients and 1 critical patient) and
 285 8 patients as the class 3 profile (1 severe patient and 7 critical patients). (B) Averaged time series of the
 286 class 1, 2 and 3 patients. Compared to the steady curve of class 1 patients, class 2 and 3 patients show
 287 different extent of inflammation, characterized by the level and width of IL-6 peak. In addition, the class
 288 3 patients show low e^* level.

290 Combing the theoretical results and clinic classification, for the *in silico* patients

291 with different immune response modes, we simulated their disease processes and
292 possible clinic outcomes, and try to put forward the available treatment strategies.

293 The main treatment strategies of COVID-19 are to prevent the potential chronic
294 infection and cytokine storm, increase the immune efficacy, and moderately inhibit
295 excessive inflammatory response. Here we consider several mostly discussed agents for
296 COVID-19: (1) Antiviral drugs (AntV), preventing viral cell entry or inhibiting the
297 production of new progeny virus (20). (2) IFN- γ , increasing innate immune response and
298 augmenting the successive adaptive immune response (21). (3) Monoclonal antibody
299 (Ig), blocking viral receptor activation, suppressing the virus and modifying the
300 inflammatory response (22). (4) Glucocorticoids (GC), preventing excessive immune
301 response that causes extensive tissue damage and inhibiting cytokines from production
302 and taking effects (23, 24).

303 We simulated the course of disease of *in silico* patients without any treatments, and
304 examined the outcome of different treatment strategies to determine the effect of the
305 above drugs and find reasonable combination of treatments. To quantify our results, we
306 defined a model-based Q value to assess patient's status and examine the effects of the
307 above medications. The scoring function Q includes patient's maximum immune
308 efficacy e_{\max}^* , respiratory capacity (defined by minimum healthy lung epithelial cells
309 $[H]_{\min}$), inflammation level (defined by maximum IL-6 level $[IL-6]_{\max}$), and whether
310 chronic infection happens. It is formulated as:

$$311 \quad Q \equiv \left(1 + q_1 \frac{e_{\max}^*}{e_c^* + e_{\max}^*} \right) \left(1 + q_2 \frac{[H]_{\min}}{[H]_c + [H]_{\min}} \right) \left(1 + q_3 \frac{[IL-6]_c}{[IL-6]_c + [IL-6]_{\max}} \right) \left(1 + q_4 \delta_{[nCov]} \right),$$

312 where we set $q_1 = 0.4, q_2 = 0.4, q_3 = 3, q_4 = 1, e_c^* = 10, H_c = 30 \times 10^6 / mL,$

313 $[IL-6]_c = 2000 pg / mL$. The Kronecker function $\delta_{[nCov]}$ equals to 1 when final viral
314 load is zero, equals to 0 when virus is not cleared.

315 We first assessed the effect of the above drugs used singly on the *in silico* patients
316 in different modes, illustrated by the change in Q value, as in Fig. 4A. Treatment
317 periods are divided into early (PAD 0~7), middle (PAD 7~14) and late stage (PAD
318 14+) referred to the estimation in (17). Effects of AntV, IFN- γ , Ig are positive during
319 early stage for their role in limiting virus invasion and tissue damage, effect of GC is
320 also positive during early stage for prevention of CRS. During middle stage, AntV and


321 IFN- γ change little of the patients' score, but AntV is still recommended during the
322 whole course of disease for preventing superinfection (this situation is seen in our
323 simulation results). Usage of GC on mode 1 and 2 patients during middle stage
324 decreases patient's Q score and is not recommended. Middle and late stage Ig benefits
325 the most on mode 3 patients for their role in cooperating with host's immunity.

326 We next tested all combinations of treatment strategies with different kinds of drugs
327 used during different stages of *in silico* patients with reasonable treatment strategies
328 summarized in Fig. S8. Antiviral drugs are recommended during the whole course of
329 infection. The mode 1 patients only need antiviral drugs for their recovery. For mode 2
330 patients, usage of IFN- γ accents innate immune efficacy and helps contain the initial
331 tissue damage, while usage of GC can reduce inflammation in advance of cytokine storm.
332 For mode 3 patients, cytokine storm lasts longer thus it is desired to prolong the usage
333 of GC during early and middle stage, while during the late stage monoclonal antibodies
334 act as backup for adaptive immunity and help clear the virus. Simulation results
335 (ensemble averaged) for mode 2 and 3 patients with the above treatment strategies are
336 shown in Fig. 4C and D. To assist with the formation of treatment plans, we adopted
337 CPCA on our simulation results and identified several early stage biomarkers
338 distinguishing the patients into mode 1, 2, and 3, including viral load, IL-6, IL-10, TNF-
339 α and Ig, shown in Fig. S5 in SM.

340 Bacterial co-infection is tested positive in more than 50% of the deceased patients
341 (2, 25), which we also found clinically. We simulated the course of disease with
342 bacterial co-infection arising from mode 2 and 3, and denoted them as mode 2*, mode
343 3.1* and mode 3.2*, where mode 3.1* patients end up with uncleared virus, while
344 mode 2* and mode 3.2* patients become virus-negative. Detailed assumptions,
345 definitions and time courses concerning bacterial co-infection are in section 7 in SM.

346 In bacterial co-infection, antibiotics (AntBio) is also included into treatment plans.
347 Similar to Fig. 4A, we assessed the effect of each drug in mode 2*, 3.1* and 3.2*
348 patients, shown in Fig. 4B. Effect of early usage of GC alone turns negative due to its
349 immunosuppressive effect, which in turn increases tissue damage and chances of
350 bacterial co-infection, leading to extensive inflammatory response induced by bacteria.
351 However, early and middle usage of GC, accompanied by AntBio, still makes a
352 favorable plan, as shown in Fig. 4E.

353 Figure 4



354

355 Fig. 4 Treatment strategies on *in silico* patients. (A) Effects of different drugs in improving patient's status
 356 (Q value) when used singly at different COVID-19 development stages. Median value of ΔQ in the
 357 whole sample is taken to assess the efficacy of the drugs. (B) Effects of different drugs on patients with
 358 bacterial co-infection. (C~E) The ensemble averaged immune response trajectories untreated (in dashed
 359 line) and the trajectories treated (in solid line) of the mode 2 patients (C), the mode 3 patients (D) and the
 360 mode 3.1* patients with bacterial co-infection (E).

361

362 We summarized our results in flowchart in Fig. 5, as a reference for an ideal procedure
363 in treating COVID-19 patients.

364 **Figure 5**



365 Fig. 5. Procedure for identifying the different immune modes and formulating proper therapeutic schedules.
366

367

368

369 Discussion

370 The immune system is a complex defense system that protects us from the pathogens,
371 including virus, bacteria, parasites and other invaders. The response and regulation of
372 immune system involve dozens of cell types and hundreds of signal molecules with
373 different ligand-receptor interactions, while these lymphocytes and molecules circulate
374 in the whole body to clear invaders and kill infected cells. The immune system usually
375 works quickly, effectively and resiliently. It prepares in advance through lymphocyte
376 abundance and pool; it learns from experience by memory lymphocyte. On the other

377 hand, it has checks and balance to prevent the over activation of immune system.

378 However, when a new virus or invader infect the host and there is no effective drug
379 treatment, the host immune system might lose the balance and exhaust the lymphocyte
380 abundance and pool. This may result in poor clinical outcome and even the epidemic
381 spread. In the last decade of the twentieth century, during the treatment of HIV, hepatitis
382 B virus and hepatitis C virus infection, the mathematical modeling interpreting
383 quantitative clinical data has made a significant contribution to understand the dynamics
384 of these viruses and the drug treatment strategy (26-30).

385 Since 2019, the ongoing of COVID-19 pandemic has sickened millions and killed
386 more than 1 million people worldwide. There is still a lack of reliable effective treatment
387 strategies toward the different immune status in patients. In this study, we constructed a
388 mathematical model to describe the dynamic response of immune system. We classified
389 the COVID-19 development processes into three typical modes of immune responses,
390 and put forward effective treatment strategies for relevant immune response processes.
391 In this work, we only focus on the immune response, and ignore other clinical symptoms
392 such as multiple system and organ failure and pathological damage of other organs. We
393 simplified the innate and adaptive immune network and chose CD4+ and CD8+ T cells
394 to motivate and orchestrate the immune responses to SARS-CoV-2 infection. More
395 quantitative and multiple time point clinical data are needed to verify our model and
396 predictions, especially the treatment strategies for different modes of immune response.
397 In our recent unpublished work, we are investigating more types of immune cells
398 including the memory T and B cells, the bacteria infection and MDSC, together with the
399 recirculation among blood, lung, lymph node, spleen and bone marrow. In addition, we
400 hope our work can help to classify the patients clinically by their early period hemograms
401 and cytokine profiles, and to choose effective treatments based on their dynamic immune
402 status. Furthermore, we hope that our approach can be adapted to other kinds of viral
403 and bacterial infections, and can be applied to describe and predict the cytokine storm
404 on CAR-T immune treatment (31, 32).

405 In summary, our work provides a quantitative framework about the complex
406 interactions between virus infection and host immune response. More feedbacks with
407 clinical treatment and data will help us to obtain the systemic and quantitative
408 understanding of dynamics that immune system responds to the infection of SARS-Cov-
409 2 virus.

410 Acknowledgements

411 The authors are grateful to Hangle Wang, Siyue Yu, Xin Gao, Dr. De Zhao for their
412 helpful cooperation and discussions.
413 The authors appreciate Dr. Zhengfan Jiang, Dr. Bin Li, Dr. San Wang, Dr. Leihan Tang,
414 Dr. Zhiyuan Li, Dr. Long Qian and Dr. Chao Tang for helpful discussions.
415 This work was supported by National Key R&D Program in China (Grants No.
416 2018YFA0900200 and 2020YFA0906900) and National Natural Science Foundation of
417 China (Grant No. 12090051).
418

419 References

- 420 1. E. Petersen *et al.*, Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *The*
421 *Lancet Infectious Diseases* **20**, e238-e244 (2020).
- 422 2. F. Zhou *et al.*, Clinical course and risk factors for mortality of adult inpatients with COVID-
423 19 in Wuhan, China: a retrospective cohort study. *The Lancet* **395**, 1054-1062 (2020).
- 424 3. C. Huang *et al.*, Clinical features of patients infected with 2019 novel coronavirus in
425 Wuhan, China. *The Lancet* **395**, 497-506 (2020).
- 426 4. J. Hadjadj *et al.*, Impaired type I interferon activity and inflammatory responses in severe
427 COVID-19 patients. *Science* **369**, 718-724 (2020).
- 428 5. A. J. Wilk *et al.*, A single-cell atlas of the peripheral immune response in patients with
429 severe COVID-19. *Nature medicine* **26**, 1070-1076 (2020).
- 430 6. N. Kaneko *et al.*, Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers
431 in COVID-19. *Cell* **183**, 143-157.e113 (2020).
- 432 7. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *New*
433 *England Journal of Medicine*, (2020).
- 434 8. J. H. Beigel *et al.*, Remdesivir for the Treatment of Covid-19 — Final Report. *New England*
435 *Journal of Medicine* **383**, 1813-1826 (2020).
- 436 9. S. T. H. Liu *et al.*, Convalescent plasma treatment of severe COVID-19: a propensity
437 score-matched control study. *Nature medicine* **26**, 1708-1713 (2020).
- 438 10. P. J. M. Brouwer *et al.*, Potent neutralizing antibodies from COVID-19 patients define
439 multiple targets of vulnerability. *Science* **369**, 643-650 (2020).
- 440 11. W. S. Lee, A. K. Wheatley, S. J. Kent, B. J. DeKosky, Antibody-dependent enhancement
441 and SARS-CoV-2 vaccines and therapies. *Nature microbiology* **5**, 1185-1191 (2020).
- 442 12. C. D. Russell, J. E. Millar, J. K. Baillie, Clinical evidence does not support corticosteroid
443 treatment for 2019-nCoV lung injury. *Lancet* **395**, 473-475 (2020).
- 444 13. H. Ledford, Coronavirus breakthrough: dexamethasone is first drug shown to save lives.
445 *Nature* **582**, 469 (2020).
- 446 14. J. B. Dowd *et al.*, Demographic science aids in understanding the spread and fatality rates
447 of COVID-19. *Proceedings of the National Academy of Sciences* **117**, 9696 (2020).
- 448 15. W.-J. Guan *et al.*, Comorbidity and its impact on 1590 patients with COVID-19 in China: a
449 nationwide analysis. *Eur Respir J* **55**, 2000547 (2020).
- 450 16. J. C. Helton, F. J. Davis, Latin hypercube sampling and the propagation of uncertainty in
451 analyses of complex systems. *Reliability Engineering & System Safety* **81**, 23-69 (2002).
- 452 17. B. Hu, H. Guo, P. Zhou, Z. L. Shi, Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev*
453 *Microbiol*, 1-14 (2020).
- 454 18. C. Rydyznski Moderbacher *et al.*, Antigen-Specific Adaptive Immunity to SARS-CoV-2 in

- 455 Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996-
456 1012.e1019 (2020).
- 457 19. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
458 *Chin Med J (Engl)* **133**, 1087-1095 (2020).
- 459 20. J. M. Sanders, M. L. Monogue, T. Z. Jodlowski, J. B. Cutrell, Pharmacologic Treatments for
460 Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **323**, 1824-1836 (2020).
- 461 21. A. Mohammed, Pathogenesis of IL-6 and potential therapeutic of IFN- γ in COVID-19. **10**,
462 307-313 (2020).
- 463 22. L. Li *et al.*, Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in
464 Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *Jama*
465 **324**, 460-470 (2020).
- 466 23. J. Cai *et al.*, The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of
467 Corticosteroid Therapy in Patients with COVID-19. *Cell Metabolism*.
- 468 24. B. Russell *et al.*, Associations between immune-suppressive and stimulating drugs and
469 novel COVID-19-a systematic review of current evidence. *Ecancermedicalscience* **14**,
470 1022-1022 (2020).
- 471 25. L. Wang *et al.*, Coronavirus disease 2019 in elderly patients: Characteristics and
472 prognostic factors based on 4-week follow-up. *J Infect* **80**, 639-645 (2020).
- 473 26. S. Bonhoeffer, R. M. May, G. M. Shaw, M. A. Nowak, Virus dynamics and drug therapy.
474 *Proceedings of the National Academy of Sciences* **94**, 6971-6976 (1997).
- 475 27. A. U. Neumann *et al.*, Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of
476 Interferon- α Therapy. *Science* **282**, 103 (1998).
- 477 28. M. A. Nowak *et al.*, Viral dynamics in hepatitis B virus infection. *Proceedings of the*
478 *National Academy of Sciences* **93**, 4398 (1996).
- 479 29. A. S. Perelson, Modelling viral and immune system dynamics. *Nature Reviews*
480 *Immunology* **2**, 28-36 (2002).
- 481 30. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, HIV-1 dynamics in
482 vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* **271**,
483 1582-1586 (1996).
- 484 31. D. C. Fajgenbaum, C. H. June, Cytokine Storm. *New England Journal of Medicine* **383**,
485 2255-2273 (2020).
- 486 32. S. L. Maude *et al.*, Chimeric Antigen Receptor T Cells for Sustained Remissions in
487 Leukemia. *New England Journal of Medicine* **371**, 1507-1517 (2014).
488